Seattle Genetics Inc

Type: Company
Name: Seattle Genetics Inc
Nationality: United States
Web Address: http://www.seagen.com/
First reported 5 hours ago - Updated 5 hours ago - 1 reports

Form 4 SEATTLE GENETICS INC For: Jun 13 Filed by: HIMES VAUGHN B

StreetInsider.com - Form 4 SEATTLE GENETICS INC For: Jun 13 Filed by: HIMES VAUGHN B ... [Published Street Insider - 5 hours ago]
First reported Jun 14 2013 - Updated Jun 14 2013 - 2 reports

ImmunoGen, Inc. (IMGN), Seattle Genetics, Inc. (SGEN), Celldex Therapeutics, Inc. (CLDX): A Trio of Cancer Immunotherapy Innovators

The cancer world has been abuzz after an exciting ASCO conference.  Bristol Myers Squibb Co. (NYSE:BMY) presented really promising updates for its PD-1 inhibitor nivolumab in late-stage melanoma, leading one Citigroup Inc. (NYSE:C) analyst to declare ... [Published InsiderMonkey.com - Jun 14 2013]
First reported Jun 14 2013 - Updated Jun 14 2013 - 1 reports
Seattle Genetics Inc
Seattle Genetics Inc

Seattle Genetics (SGEN) Could Fall Through $31.18 Support Level

Seattle Genetics Inc. (NASDAQ: SGEN) closed Thursday's trading session at $32.81. In the past year, the stock has hit a 52-week low of $21.05 and 52-week high of $39.00. Seattle Genetics (SGEN) stock has been showing support around $31.18 and resistance ... [Published MarketIntelligenceCenter.com - Jun 14 2013]
First reported Jun 13 2013 - Updated Jun 13 2013 - 1 reports

Should You Avoid Seattle Genetics, Inc. (SGEN)?

Seattle Genetics, Inc. (NASDAQ: SGEN ) was in 8 hedge funds’ portfolio at the end of the first quarter of 2013. SGEN has experienced a decrease in hedge fund interest lately. There were 8 hedge funds in our database with SGEN positions at the end of the ... [Published InsiderMonkey.com - Jun 13 2013]
First reported Jun 11 2013 - Updated Jun 12 2013 - 3 reports
bendamustine
bendamustine

Seattle Genetics starts phase I/II trial of ADCETRIS in combo with bendamustine for HL patients after initial relapse

Seattle Genetics, Inc. has started phase I/II clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with bendamustine for patients with Hodgkin lymphoma (HL) after first relapse. The multi-phase study is divided into two cohorts to determine ... [Published PharmaBiz - Jun 12 2013]
First reported Jun 12 2013 - Updated Jun 12 2013 - 1 reports

Seattle Genetics announces encouraging data from cancer trials

Seattle Genetics, Inc., a biotechnology company, has announced data from ongoing clinical development programs for ADCETRIS in frontline Hodgkin lymphoma, or HL, and mature T-cell lymphoma, or MTCL, and progress with collaborator antibody-drug conjugate, ... [Published Individual.com - Jun 12 2013]
First reported Jun 10 2013 - Updated Jun 11 2013 - 2 reports
ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc. (ACAD) Soars On Hedge Fund Investment

One of the best ways that retail investors can try to decide which stocks will make for a promising investment is to look at what the hedge funds are doing. This can be achieved by examining a few official filings such as 13F, 13D, and 13G reports. 13F ... [Published InsiderMonkey.com - Jun 10 2013]
First reported Jun 10 2013 - Updated Jun 10 2013 - 2 reports

Seattle Genetics Announces Initiation of Phase 1/2 Trial of ADCETRIS® (Brentuximab Vedotin) in Combination …

Trial Rationale Supported by Encouraging Data Reported on the Activity and Tolerability of ADCETRIS in the Treatment of Salvage HLBOTHELL, Wash.--(BUSINESS WIRE)-- (SGEN) today announced the initiation of a phase 1/2 clinical trial evaluating ADCETRIS ... [Published Yahoo! Finance - Jun 10 2013]
First reported Jun 06 2013 - Updated Jun 07 2013 - 2 reports

Seattle Genetics Highlights ADCETRIS

® (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate (ADC) Collaborator Data at ASCO Annual Meeting -ADCETRIS Phase 3 ECHELON-1 and ECHELON-2... ... [Published Drugs.com - Jun 07 2013]
First reported Jun 05 2013 - Updated Jun 05 2013 - 2 reports

3 Pharmaceuticals With Strong Potential

Home » Blogs » I will look into 3 pharmaceutical companies that should outperform large-cap firms in the industry in the long-term. I ran a screen that scans for Pharmaceutical companies that have a solid IBD Ranking and promising pipelines of future ... [Published BioPortfolio - Jun 05 2013]
First reported Jun 02 2013 - Updated Jun 02 2013 - 2 reports

Seattle Genetics Presents Frontline HL And MTCL Clinical Development Programs

Seattle Genetics, Inc. (SGEN: Quote) announced the presentation about ongoing clinical development programs for ADCETRIS in frontline Hodgkin lymphoma and mature T-cell lymphoma and progress of collaborator antibody-drug conjugate programs at the 49th ... [Published RTTNews.com - Jun 02 2013]
First reported May 21 2013 - Updated May 22 2013 - 2 reports

Hodgkin Lymphoma: The Top Secret Strategy Of Seattle Genetics Revealed

By now most every investor has heard the name, Seattle Genetics (SGEN) a once small, still developmental biotechnology company with a well recognized oncology drug in Adcetris. Many analysts that cover the stock including the well-respected bio-blogger ... [Published Seeking Alpha - May 22 2013]

Quotes

...Dr. Peter B Corr, Chairman of ADC Therapeutics said: "We are very excited to be developing an ADC with our new partner Genmab and incorporating our next generation PBD-based toxins into this product. Our warhead payload technology enjoys exquisite potency, optimised conjugation and pharmaceutical properties that maintain activity in highly resistant cancers. Our pre-clinical data for this product indicate the potential for curative efficacy in highly resistant populations at low ADC doses of this product in several oncology indications, an area with critical unmet needs" .  This agreement does not affect Genmab's 2013 financial guidance...
Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Com ... [Published SPi World News - 23 hours ago]
...by the interest in this therapeutic approach at the ASCO annual meeting," said Clay B Siegall, Ph D , President and CEO of Seattle Genetics. "As the first ADC to be approved by the FDA in this new class, we are focused on broadening the evaluation of ADCETRIS in earlier lines of therapy with our ongoing ECHELON-1 and ECHELON-2 global Phase III trials, which are designed to redefine the standard of care for frontline treatment of HL and MTCL. While we advance our internal programs, our collaborators are making important progress utilizing our ADC technology. Notably, Genentech is presenting encouraging Phase I data for two ADC candidates in solid tumor settings."
Seattle Genetics announces encouraging data from cancer trials [Published Individual.com - Jun 12 2013]
The online publication, ahead of print, titled "Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma" by Sosa et al., is available at: http://0-www.ncbi.nlm.nih.gov.elis.tmu.edu.tw/pubmed/23721245...
OXiGENE Reports Publication of Final FACT Study Data in Journal Thyroid; Immunomedics' 90Y-Epratu ... [Published BioMedReports - Jun 11 2013]
...xenografts of little relevance to individual patients," Thomas Daniel, Celgene's president of research and early development, said in a statement. "The Presage platform addresses this challenge, permitting rapid assessment of drug candidates and combinations in relevant models, with potential to base critical drug development decisions on in vivo response data." Bluebird Bio: in March 2013 Celgene forked over an undisclosed upfront sum and agreed to pay upup to $225 million in milestones to Cambridge, MA based...
Celgene Moves Fast And Early In Expanding Its Pipeline [Published Seeking Alpha - Jun 10 2013]

More Content

All (197) | News (91) | Reports (9) | Blogs (51) | Audio/Video (0) | Fact Sheets (0) | Press Releases (46)
sort by: Date | Relevance
Form 4 SEATTLE GENETICS INC For: Jun 13 Filed b... [Published Street Insider - 5 hours ago]
Immunotherapy: Four Companies on the Verge of C... [Published Minyanville - 15 hours ago]
NASDAQ Announces Changes to Q-50 Index [Published Street Insider - 15 hours ago]
Genmab and ADC Therapeutics Enter Co-Developmen... [Published SPi World News - 23 hours ago]
Genmab And ADC Therapeutics Enter Co-Developmen... [Published TheStreet.com - 23 hours ago]
Genmab and ADC Therapeutics Enter Co-Developmen... [Published NASDAQ OMX - 23 hours ago]
Seattle Genetics Partnering 2005-2013 - new com... [Published TransWorldNews - Jun 15 2013]
Quarterly Changes to the NASDAQ Q-50 Index [Published OSIX News - Jun 15 2013]
ImmunoGen, Inc. (IMGN), Seattle Genetics, Inc. ... [Published InsiderMonkey.com - Jun 14 2013]
A Trio of Cancer Immunotherapy Innovators [Published Motley Fool - Jun 14 2013]
Seattle Genetics (SGEN) Could Fall Through $31.... [Published MarketIntelligenceCenter.com - Jun 14 2013]
The World Market for Orphan Drugs [Published MarketResearch.com - Jun 14 2013]
KaloBios: An Undervalued Pharmaceutical Company... [Published Seeking Alpha - Jun 13 2013]
Should You Avoid Seattle Genetics, Inc. (SGEN)? [Published InsiderMonkey.com - Jun 13 2013]
Seattle Genetics starts phase I/II trial of ADC... [Published PharmaBiz - Jun 12 2013]
Seattle Genetics announces encouraging data fro... [Published Individual.com - Jun 12 2013]
SGEN Starts Adcetris Phase I/II Study - Analyst... [Published Quote.com Canada - Jun 11 2013]
SGEN Starts Adcetris Phase I/II Study Zacks [Published Yahoo! Finance - Jun 11 2013]
5 best-performing biotech stocks of 2013 [Published MSN Money - Jun 11 2013]
Critical Alerts For International Business Mach... [Published PR Newswire: Financial Services - Jun 11 2013]
Five Best-Performing Biotech Stocks of 2013 (So... [Published TheStreet.com - Jun 11 2013]
OXiGENE Reports Publication of Final FACT Study... [Published BioMedReports - Jun 11 2013]
Seattle Genetics Announces Initiation of Phase ... [Published Drugs.com - Jun 10 2013]
Analysts’ Downgrades for June, 10th (AHL, AMNB,... [Published American Banking News - Jun 10 2013]
Seattle Genetics Downgraded to Neutral at Zacks... [Published American Banking News - Stock Ratings - Jun 10 2013]
Celgene Moves Fast And Early In Expanding Its P... [Published Seeking Alpha - Jun 10 2013]
ACADIA Pharmaceuticals Inc. (ACAD) Soars On Hed... [Published InsiderMonkey.com - Jun 10 2013]
Acadia Pharmaceuticals Soars On Hedge Fund Inve... [Published Motley Fool - Jun 10 2013]
Seattle Genetics Announces Initiation of Phase ... [Published Yahoo! Finance - Jun 10 2013]
Seattle Genetics (SGEN) Initiates ADCETRIS Phas... [Published Street Insider - Jun 10 2013]
1 2 3 4 5 6 7
In Focus
  •  
Clay B Siegall, John Peter, William Blair, [more]
  •  
Starbucks Corporation, NIKE Inc, Adobe Systems Inc, [more]
  •  
Bill & Melinda Gates Foundation, FDA Food & Drug Administration, American Society of Clinical Oncology, [more]
  •  
Brentuximab-Vedotin, Healthcare Conference, 8-k, [more]
  •  
Adcetris, bendamustine, Kadcyla, [more]
  •  
Chicago, Boston (Massachusetts, United States), Bothell (United States), [more]
  •  
Canada, United States, Japan, [more]
  •  
Diseases, Medication, Research & Development, [more]
  •  
Banking & Financial Services, Health, Logistics & Shipping, [more]
MarketIntelligenceCenter.com, Business Wire Health News, Street Insider, [more]
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Seattle Genetics (SGEN) Could Fall Through $31.... [Published MarketIntelligenceCenter.com - Jun 14 2013]
Seattle Genetics Inc. (NASDAQ: SGEN) closed Thursday's trading session at $32.81. In the past year, the stock has hit a 52-week low of $21.05 and 52-week high of $39.00. Seattle Genetics (SGEN) stock has been showing support around $31.18 and resistance ...
Seattle Genetics (SGEN) Showing Bearish Technic... [Published MarketIntelligenceCenter.com - Jun 10 2013]
Seattle Genetics Inc. (NASDAQ: SGEN) closed Friday's trading session at $34.49. In the past year, the stock has hit a 52-week low of $21.05 and 52-week high of $39.00. Seattle Genetics (SGEN) stock has been showing support around $33.72 and resistance ...
Potential Seattle Genetics (SGEN) Trade Targets... [Published MarketIntelligenceCenter.com - Jun 04 2013]
Seattle Genetics Inc. (NASDAQ: SGEN) closed Monday's trading session at $35.08. In the past year, the stock has hit a 52-week low of $19.17 and 52-week high of $39.00. Seattle Genetics (SGEN) stock has been showing support around $31.71 and resistance ...
Seattle Genetics (SGEN) Showing Bullish Technic... [Published MarketIntelligenceCenter.com - May 29 2013]
Seattle Genetics Inc. (NASDAQ: SGEN) closed Tuesday's trading session at $35.90. In the past year, the stock has hit a 52-week low of $19.03 and 52-week high of $39.00. Seattle Genetics (SGEN) stock has been showing support around $35.02 and resistance ...
Seattle Genetics (SGEN) Showing Bullish Technic... [Published MarketIntelligenceCenter.com - May 22 2013]
Seattle Genetics Inc. (NASDAQ: SGEN) closed Tuesday's trading session at $35.73. In the past year, the stock has hit a 52-week low of $19.03 and 52-week high of $39.00. Seattle Genetics (SGEN) stock has been showing support around $35.11 and resistance ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Critical Alerts For International Business Mach... [Published PR Newswire: Financial Services - Jun 11 2013]
Seattle Genetics Announces Initiation of Phase ... [Published Business Wire Health News - Jun 10 2013]
Seattle Genetics Highlights ADCETRIS® (Brentuxi... [Published Business Wire Health News - Jun 02 2013]
Seattle Genetics to Present at Upcoming Investo... [Published Business Wire Health News - May 29 2013]
Seattle Genetics Announces ADCETRIS® (Brentuxim... [Published Business Wire Health News - May 14 2013]
1 2 3 4 5 6 7 8 9 10
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.